Bicycle Therapeutics plc
BCYC
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5ā¦ read more
Healthcare
Biotechnology
6 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$6.87
Price+1.48%
$0.10
1Y
Price
Market Cap
$476.012m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-486.6%
EBITDA Margin-503.7%
Net Profit Margin-612.3%
Free Cash Flow MarginRevenue
$28.339m
-19.7%
1y CAGR+32.5%
3y CAGR+30.3%
5y CAGREarnings
-$250.660m
-48.3%
1y CAGR-34.0%
3y CAGR-42.7%
5y CAGREPS
-$3.61
-24.5%
1y CAGR-5.1%
3y CAGR-14.4%
5y CAGRBook Value
$618.479m
$763.954m
Assets$145.475m
Liabilities$5.743m
DebtDebt to Assets
0.8%
-
Debt to EBITDAFree Cash Flow
-$242.203m
-45.9%
1y CAGR-55.8%
3y CAGR-173.1%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company